Skip to main content
  • Platelet-Guided Switch to Clopidogrel Misses Primary Endpoint in VERONICA Trial

    Findings from the randomized EPIC17-VERONICA trial presented at Transcatheter Cardiovascular Therapeutics (TCT) 2026 showed that platelet function-guided de-escalation from potent P2Y12 inhibitors to clopidogrel did not significantly improve one-year clinical outcomes in patients with acute coronary syndrome (ACS).

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details